Motapizone (NAT 05-239) is a selective PDE3 inhibitor that moderately reduces cytokine release in lipopolysaccharide (LPS)-stimulated alveolar macrophages and suppresses human platelet aggregation by elevating intracellular cAMP levels [1] [2].